Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Down After Analyst Downgrade

Posted by on Aug 26th, 2026

Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) gapped down before the market opened on Wednesday after Wedbush lowered their price target on the stock from $130.00 to $123.00. The stock had previously closed at $107.36, but opened at $92.41. Wedbush currently has an outperform rating on the stock. Spyre Therapeutics shares last traded at $94.5630, with a volume of 496,905 shares.

Other equities research analysts have also recently issued reports about the stock. Robert W. Baird set a $120.00 price objective on shares of Spyre Therapeutics in a research report on Wednesday, August 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Spyre Therapeutics in a report on Thursday, June 4th. Wall Street Zen cut shares of Spyre Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Citigroup raised their target price on Spyre Therapeutics from $64.00 to $97.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Finally, Wolfe Research downgraded Spyre Therapeutics from an “outperform” rating to a “peer perform” rating in a research report on Tuesday, July 28th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $109.69.

Check Out Our Latest Stock Analysis on SYRE

Insider Transactions at Spyre Therapeutics

In other news, Director Jeffrey W. Albers sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $104.47, for a total value of $522,350.00. Following the completion of the transaction, the director owned 5,000 shares of the company’s stock, valued at approximately $522,350. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Michael Thomas Henderson sold 20,000 shares of Spyre Therapeutics stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $100.00, for a total transaction of $2,000,000.00. Following the completion of the transaction, the director owned 68,606 shares of the company’s stock, valued at $6,860,600. This trade represents a 22.57% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 142,167 shares of company stock worth $12,779,292 in the last three months. Company insiders own 15.69% of the company’s stock.

Key Headlines Impacting Spyre Therapeutics

Here are the key news stories impacting Spyre Therapeutics this week:

  • Positive Sentiment: Both SPY072 doses produced statistically significant improvements versus placebo on at least one key measure, including DAS28-CRP, ACR20, and exploratory ACR50 endpoints. The results support continued development of SPY072 and Spyre’s broader immunology pipeline. Spyre Announces Topline Results from the Rheumatoid Arthritis Sub-study
  • Positive Sentiment: Wedbush maintained an Outperform rating while lowering its price target to $123 from $130. BTIG Research likewise maintained a Buy rating and reduced its target to $121 from $132. Both targets imply substantial upside from recent trading levels, although the reductions indicate more cautious expectations. Wedbush Adjusts Price Target on Spyre Therapeutics
  • Neutral Sentiment: Brokerage coverage remains generally favorable, with Spyre receiving an average “Moderate Buy” recommendation. However, the mixed target-price revisions suggest analysts are incorporating greater near-term uncertainty following the trial update. Spyre Receives Moderate Buy Recommendation
  • Negative Sentiment: The market reaction to the SPY072 rheumatoid arthritis data was sharply negative, making the trial readout the principal apparent catalyst for the decline. Spyre’s high valuation means investors may demand especially strong and clearly differentiated clinical results from upcoming readouts.

Institutional Trading of Spyre Therapeutics

A number of large investors have recently modified their holdings of SYRE. GAMMA Investing LLC grew its holdings in shares of Spyre Therapeutics by 26.8% during the second quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock worth $59,000 after buying an additional 140 shares during the last quarter. Optimize Financial Inc increased its stake in shares of Spyre Therapeutics by 1.5% during the fourth quarter. Optimize Financial Inc now owns 25,331 shares of the company’s stock worth $830,000 after acquiring an additional 364 shares during the period. Mercer Global Advisors Inc. ADV boosted its holdings in Spyre Therapeutics by 0.5% in the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 106,664 shares of the company’s stock valued at $1,788,000 after purchasing an additional 522 shares in the last quarter. Summit Securities Group LLC purchased a new position in shares of Spyre Therapeutics during the 1st quarter worth approximately $28,000. Finally, California State Teachers Retirement System raised its stake in shares of Spyre Therapeutics by 1.8% during the 2nd quarter. California State Teachers Retirement System now owns 33,201 shares of the company’s stock worth $497,000 after buying an additional 603 shares in the last quarter. Hedge funds and other institutional investors own 80.39% of the company’s stock.

Spyre Therapeutics Stock Performance

The firm has a market capitalization of $8.35 billion, a price-to-earnings ratio of -48.49 and a beta of 3.03. The firm has a fifty day moving average price of $98.16 and a 200 day moving average price of $71.79.

Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.40. Research analysts predict that Spyre Therapeutics, Inc. will post -2.62 earnings per share for the current fiscal year.

Spyre Therapeutics Company Profile

(Get Free Report)

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.

Featured Stories

Receive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.